Cargando…
Trametinib-Resistant Melanoma Cells Displaying MITF(high)/NGFR(low)/IL-8(low) Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge
Despite significant advances in targeted therapies against the hyperactivated BRAF(V600)/MEK pathway for patients with unresectable metastatic melanoma, acquired resistance remains an unsolved clinical problem. In this study, we focused on melanoma cells resistant to trametinib, an agent broadly use...
Autores principales: | Koziej, Paulina, Kluszczynska, Katarzyna, Hartman, Mariusz L., Czyz, Malgorzata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178474/ https://www.ncbi.nlm.nih.gov/pubmed/37175614 http://dx.doi.org/10.3390/ijms24097891 |
Ejemplares similares
-
Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal
por: Hartman, Mariusz L., et al.
Publicado: (2023) -
TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells
por: Hartman, Mariusz L., et al.
Publicado: (2019) -
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations
por: Hartman, Mariusz L., et al.
Publicado: (2016) -
MITF in melanoma: mechanisms behind its expression and activity
por: Hartman, Mariusz L., et al.
Publicado: (2014) -
Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019)